# Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clinical.html) · 2026-11-18 · Medicine
Page: https://themorning.science/story/targeting-immune-overactivity-in-down-syndrome-shows-promise-in-phase-2-clinical-b99b4c7b56e203ad
Kind: research · Impact: medium

## In brief

- Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz ran a first-of-its-kind clinical trial.
- The trial was a phase 2 study of a medication that targets immune overactivity in people with Down syndrome.
- The medication reduced underlying inflammation in participants.

## Why it matters

It offers early clinical evidence that immune overactivity, and the inflammation linked to it, can be targeted in people with Down syndrome, a condition that has had few tested treatment options.

## Coverage

- [Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial](https://medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clinical.html) — Medical Xpress - latest medical and health news stories, 2026-11-18

Tags: down syndrome, immunology, inflammation, clinical trial, phase 2

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
